Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. Our diverse pipeline includes eteplirsen, our lead program for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. We aim to build a leading, independent biopharmaceutical company dedicated to translating RNA-based science into transformational therapies for patients who face significant unmet medical needs.
|View printer-friendly version|
|Sarepta Therapeutics Announces Agreement for Acquisition of Manufacturing Facility in Massachusetts|
State-of-the-art 60,000 square foot facility enhances internal manufacturing capability
“This strategic acquisition complements our existing internal
manufacturing capability and global network of suppliers,” said
Sarepta is the global leader in the development of phosphorodiamidate morpholino oligomer (PMO) chemistries for RNA therapeutics, with nearly a decade of experience producing drug supply for use in basic research and clinical trials. The Company plans to use the facility to further enhance and scale its proprietary manufacturing processes for PMO chemistries. In addition, the facility will be used to manufacture drug supply to support clinical trials of Sarepta’s exon skipping therapies for DMD, as well as research and development of future potential products and modified PMO chemistries.
The multifunctional facility was constructed in 1996 and upgraded in 2006, and has been qualified under Current Good Manufacturing Practice (cGMP) regulations. When fully operational, the facility supports approximately 40 technicians and support staff. In addition, the acquisition includes 26 acres of land available for future potential expansion.
Forward-Looking Statements and Information
This press release contains statements that are forward-looking,
including the statements about the potential acquisition by Sarepta of a
new manufacturing facility and other property, the expected time for
closing the acquisition, the planned uses for the property being
acquired and benefits of the acquisition to Sarepta and its business
operations, within the meaning of Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934. These
forward-looking statements involve risks and uncertainties, some of
which are beyond Sarepta’s control, including: the acquisition may not
successfully close for various reasons including termination of the
agreement by either party or the failure of closing conditions to be met
and Sarepta’s ability to use the property and achieve benefits from the
property as planned may be negatively impacted by various factors
including availability of resources, government or agency decisions and
unexpected changes in applicable laws. These risks should be considered
together with those included in the “Risk Factors” section of Sarepta’s
Quarterly Report on Form 10-Q for the quarterly period ended
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward–looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company’s Securities and Exchange Commission filings.